Region Stockholm – SLSO

6 trials Academic / non-commercial

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

0 Recruiting

1 Completed trials

1 Countries active

10 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 2 Phase II: 3 Phase IV: 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Multiple sclerosis relapse prophylaxis 1 Tick-borne viral encephalitis 1 Relapsing multiple sclerosis 1

Top IMPs

(4R)-1-[(3-(11C)METHYLPYRIDIN-4-YL)METHYL]-4-(3,4,5-TRIFLUOROPHENYL)PYRROLIDIN-2-ONE 1 CETIRIZINE DIHYDROCHLORIDE 1 EXENATIDE 1 INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED, INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED 1 METHYLPREDNISOLONE 1 PARACETAMOL 1 PSILOCYBINE 1 TOLEBRUTINIB 1

All trials

6 total

Evaluation of Influenza Vaccine Immune Response in Obesity (VaccObFlu) Pending

2025-522698-13-00 Phase IV 1 country INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1…
Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT) - proof of concept Pending

2025-523465-21-00 Phase III 1 country CETIRIZINE DIHYDROCHLORIDE; METHYLPREDNISOLONE; PARACETAMOL
Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) Pending

2025-523476-23-00 Phase II 1 country
A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment … Pending

2025-523892-50-00 Phase III 1 country TOLEBRUTINIB
CAPSI - Cancer related major depression treated with a single dose of psilocybin - a multicenter randomized placebo controlled double blind … Halted

2023-505532-35-00 Phase II 1 country (4R)-1-[(3-(11C)METHYLPYRIDIN-4-YL)METHYL]-4-(3,4,5-TRIFLUOROPHENYL)PYRROLIDIN-2…
Effect of Exenatide on disease progression in early Parkinson’s disease. Ended

2024-520069-30-00 Phase II 1 country EXENATIDE

Showing 1–6 of 6 trials

← All sponsors A–Z